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Background: Granulocytemacrophage-colony stimulating factor (GM-CSF) is critically required for the induction
of experimental autoimmune myocarditis (EAM), a model of post-inﬂammatory dilated cardiomyopathy. Its
speciﬁc role in the progression of myocarditis into end stage heart failure is not known.
Methods and results: BALB/c mice were immunizedwithmyosin peptide and complete Freund's adjuvant at days
0 and 7. Heart-inﬁltrating inﬂammatory CD133+ progenitors were isolated from inﬂamed hearts at the peak of
inﬂammation (day 21). In the presence of GM-CSF, inﬂammatory CD133+ progenitors up-regulated integrin,
alpha X (CD11c), class II major histocompatibility complex, CD80 and CD86 co-stimulatory molecules reﬂecting
an inﬂammatory dendritic cell (DC) phenotype. Inﬂammatory DCs stimulated antigen-speciﬁc CD4+ T cell pro-
liferation and induced myocarditis after myosin peptide loading and adoptive transfer in healthy mice. More-
over, GM-CSF treatment of mice after the peak of disease, between days 21 and 29 of EAM, transiently
increased accumulation of inﬂammatory DCs in the myocardium. Importantly, bone marrow-derived CD11b+
monocytes, rather than inﬂammatory CD133+ progenitors represent the dominant cellular source of
heart-inﬁltrating inﬂammatory DCs in EAM. In contrast, GM-CSF treatment neither affected numbers of
heart-inﬁltrating CD45+ and CD3+ T cells nor the development of post-inﬂammatory ﬁbrosis.
Conclusions: GM-CSF treatment promotes formation of inﬂammatory DCs in EAM. In contrast to the active roles
of GM-CSF and DCs in EAM induction, GM-CSF-induced inﬂammatory DCs neither prevent resolution of active
inﬂammation, nor contribute to post-inﬂammatory cardiac remodelling. This article is part of a Special Issue
entitled: Cardiomyocyte Biology: Cardiac Pathways of Differentiation, Metabolism and Contraction.© 2012 Elsevier B.V. All rights reserved.1. Introduction
Inﬂammatory dilated cardiomyopathy (iDCM) refers to a subtype
of dilated cardiomyopathy characterized by increased cardiac inﬂam-
mation, progressively impaired cardiac contractility, ﬁbrosis, and ven-
tricular dilation. iDCM often results from virus or parasite-triggered
myocarditis [1], but autoimmune mechanisms had been recognized
to promote disease progression and iDCM development.
The experimental autoimmune myocarditis (EAM) model mirrors
important mechanisms of iDCM development. In this model, auto-
reactive T helper cells mediate cardiac inﬂammation. EAM can be in-
duced in susceptible mouse strain by immunization with heart-
speciﬁc alpha myosin heavy chain (αMyHC) peptide together withocyte Biology: Cardiac Pathways
vascular Research Department,
erstrasse 190, CH-8057 Zürich,
27.
l rights reserved.complete Freund's adjuvant (CFA) [2]. In the EAMmodel, myocarditis
severity, as reﬂected by the extent of myocardial inﬂammatory inﬁl-
trates peaks three weeks after the ﬁrst immunization. Later on, in-
ﬂammation largely resolves, but the process of pathological
remodelling continues and many animals develop ventricular dilation
and heart failure on follow-up. Innate signalling and also selected cy-
tokines were reported to promote transition of myocarditis to the end
stage heart failure phenotype [3–5]. The precise mechanisms of iDCM
development after resolution of active inﬂammation remain elusive.
Granulocyte macrophage-colony stimulating factor (GM-CSF) rep-
resents a therapeutically used cytokine in haematopoietic stem cell
transplantations [6]. One of the most important biological functions
of GM-CSF is the stimulation of dendritic cell (DC) formation [7].
GM-CSF was reported to induce DC differentiation of mouse and
human hematopoietic progenitor cells [7–9]. GM-CSF is produced at
low levels under steady-state conditions, but its production is greatly
enhanced during inﬂammation. It is widely believed that GM-CSF re-
quirement for DC lineage development is marginal in homeostasis
[10], whereas during acute injury it promotes generation of
935P. Blyszczuk et al. / Biochimica et Biophysica Acta 1833 (2013) 934–944inﬂammatory DCs [11–13]. Recently, this concept has been, however,
questioned [14]. Various cell types including activated myeloid cells,
T cells, ﬁbroblasts, endothelial cells, and also muscle cell were
reported to produce GM-CSF [15,16]. In humans, elevated GM-CSF
levels were observed not only during acute myocarditis [17], but
also in other cardiovascular disorders [18–21].
GM-CSF is particularly important for conversion of monocytes into
DCs [8,13]. These, so called, monocyte-derived DCs have been reported
to produce pro-inﬂammatory cytokines and to effectively present anti-
gen, stimulating CD4+ and CD8+ T cell responses, and to migrate to in-
ﬂammatory sites [12,22,23]. They are, therefore, believed to play an
important role in innate and adaptive immunity. Bone marrow-
derived, αMyHC peptide-loaded DCs were generated in the presence
of GM-CSF induce CD4+ T cell-mediated autoimmune myocarditis
after transfer into recipient mice [24]. Animal studies using transgenic
mice or blocking antibodies further demonstrated that GM-CSF is criti-
cally involved in development of various organ-related autoimmune
diseases [25–28]. In EAM,myocarditis severity is reduced in GM-CSF de-
ﬁcient mice immunized with αMyHC/CFA due to impaired cytokine
production and limited expansion of autoreactive T helper cells [25].
The role of GM-CSF during the chronic, post-inﬂammatory phase
of EAM, however, is not known yet. This post-inﬂammatory phase re-
ﬂects the morphological transition of acute cardiac inﬂammation into
the typical dilated and ﬁbrotic end stage heart failure phenotype. In
view of novel therapeutic strategies, it is of upmost importance to un-
derstand the relevant mechanisms, which drive post-inﬂammatory
remodelling and heart failure progression. Here, we showed that
GM-CSF injections efﬁciently boosted inﬂammatory DC formation in
the myocardium of mice in the post-inﬂammatory phase. However,
resolution of myocarditis, ﬁbrosis development and T cell relapses
were not affected in GM-CSF-treated animals.
2. Material and methods
2.1. Mice
BALB/cJ and DO11.10-tg (on BALB/c background) mice were orig-
inally purchased from Jackson Laboratory. BALB/cJ were thereafter
bred in our facility as BALB/cRsko mice (hereafter referred to as
BALB/c). Animal experiments were performed in accordance with
Swiss federal law and were approved by the local authorities.
2.2. EAM induction
Mice were subcutaneously injected with 150 μg of αMyHC
(Ac-RSLKLMATLFSTYASADR-OH; Caslo) peptide emulsiﬁed 1:1 with
Complete Freund's Adjuvant (CFA, Difco) on days 0 and 7, as de-
scribed previously [29].
2.3. Cytokine treatments
200 μg/kg of recombinant GM-CSF (Peprotech) were intravenously
injected every second day into αMyHC/CFA-treated mice between
days 21 and 29. Control mice received solvent only.
2.4. Histopathology and immunohistochemistry
Hearts were formalin-ﬁxed and parafﬁn-embedded. Myocarditis
severity was scored on hematoxylin–eosin stained heart sections
using a semi-quantitative 0–4 scale: 0 — no inﬂammatory inﬁltrates;
1 — small foci of inﬂammatory cells between myocytes; 2 — larger
foci of >100 inﬂammatory cells; 3 — >10% of a cross-section
involved; 4 — >30% of a cross-section involved.
Heart sectionswere stainedwith rabbit anti-mouse CD45 1: 250 (BD
Bioscience) or rabbit anti-mouse CD3 1:500 (Neomarkers). Fibrosis
severity was scored on Masson's Trichrom staining. Fibrotic areas andimmunopositive cells were quantiﬁed using analySIS FIVE software
(Olympus).
2.5. Cell cultures
2.5.1. Isolation, expansion and differentiation of heart-inﬁltrating
CD133+ cells
Myocarditis-positive hearts were perfused, dissected and digested
with Liberase Blendzyme (Roche) for 45 min at 37 °C and tissue sus-
pensions were passed sequentially through 70 μm and 40 μm cell
strainers. Cardiomyocyte-free cell population was obtained by low
speed centrifugation (50 g, 2 min). CD133+ cells were isolated by pos-
itive selection using anti-CD133-PE antibody (eBioscience) and mag-
netic anti-PE-microbeads (both Miltenyi) or using FACS sorting (cells
were gated for CD45 (BD Bioscience) and CD133). Enriched CD133+
cells were plated onto gelatine-coated cell culture plates and
cultured in the Iscove's Modiﬁed Dulbecco's Medium supplemented
with 20% fetal bovine serum, 1:100 penicillin/streptomycin, 100 μM
non-essential amino acids, 1 mM sodium pyruvate and 0.2 mM
β-mercaptoethanol (all Invitrogen). Dendritic cell differentiation was
induced with 10 ng/mL GM-CSF.
2.5.2. Generation of bone marrow-derived dendritic cells (bmDCs) and
monocytes
Freshly isolated bonemarrowof naïve BALB/cmousewas cultured in
the RPMI supplemented with 10% fetal bovine serum, 1:100 penicillin/
streptomycin, 100 μM non-essential amino acids, 1 mM sodium pyru-
vate and 0.2 mM β-mercaptoethanol (all Invitrogen) in the presence
of 10–20 ng/mL GM-CSF (produced in our laboratory) for 7–12 days
to generate bmDCs or in the presence of 10 ng/mL M-CSF (PeproTech)
for 5–7 days to generate bone marrow-derived monocytes.
2.6. Adoptive transfer
Before adoptive transfer, cultured cells were harvested and passed
through 40 μm cell strainers. To attenuate EAM, animals received in-
travenously 106 CD133+ progenitors or CD133-derived dendritic
cells at day 7 after αMyHC/CFA immunization. For EAM induction,
CD133+ progenitors, CD133-derived dendritic cells or bmDCs were
pulsed with 10 μg/mL αMyHC peptide, activated with 0.1 μg/mL lipo-
polysaccharide (LPS; List Labs) and 5 μg/mL anti-CD40 prior to intra-
peritoneal injection of 5×105cells/mouse at days 0, 2 and 4.
2.7. Flow cytometry and FACS
Single cell suspensions were incubated 30 min on ice with the
appropriate combination of ﬂuorochrome- or biotin-conjugated
antibodies. The following antibodies were used: ﬂuorochrome-
conjugated antibodies: anti-CD45-PE- or FITC-conjugated (clone
30-F11), anti-CD11b-APC-conjugated (M1/70), anti-CD11c-APC
conjugated (HL3), anti-I-A/I-E-FITC-conjugated (2G9, all BD Biosci-
ence), anti-CD4-PE-conjugated (RM4-5), anti-CD62L-APC-conjugated
(MEL-14), anti-CD69-PECy7-conjugated (H1.2F3, all Biolegend)
and biotin-conjugated antibodies: anti-CD80 (16-10A1), anti-CD86
(GL1), anti-CD133 (13A4), anti-CD44 (clone IM7, all eBioscience).
Streptavidin-APC (BD Bioscience) was used to detect biotin-
conjugated antibodies. Cells were analysedwith the FACSCanto analyser
(BD Bioscience) and FlowJo software (Tree Star).
2.8. T cell proliferation assays
αMyHC-speciﬁc Th17 cell lines were generated as described previ-
ously [30,31]. 5×104 αMyHC-speciﬁc Th17 cells were re-stimulated
with 2 μg/mL αMyHC on 2×105 irradiated splenocytes in the presence
of 5 ng/mL IFN-γ (Peprotech) with or without 5×104 CD133+ or
CD133-derived cells for 48 h. Proliferation was analysed by measuring
936 P. Blyszczuk et al. / Biochimica et Biophysica Acta 1833 (2013) 934–944[Methyl-3H]-thymidine (PerkinElmer) incorporation during the last
8 h. [Methyl-3H]-thymidine was detected using a conventional scintil-
lation counter.2.9. Antigen-speciﬁc CD4+ T cell proliferation
CD4+ T cells were isolated from spleens of DO11.10-tgmice using
magnetic beads (Miltenyi Biotec) and labelled with 2.5 μM CFSE
(7 min at room temperature). CD133+ progenitors or CD133+-
derived DCs were pre-treated without or with 2 μg/mL OVA323–3390
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Fig. 1. GM-CSF differentiates heart-inﬁltrating CD133+ progenitors into DCs. Heart-inﬁltra
(control, black) or with 10 ng/mL GM-CSF (white) for 14 days. (A–B) Representative immun
itors cultured in the absence (A, control) or presence of GM-CSF (B, +GM-CSF). DAPI (blue
marker CD133 (C), monocyte marker CD11b (D), DC marker CD11c (E), MHC class II (F), co
respective analyses. n=8, p values computed with two-tailed Student's t-test.peptide (Anaspec) for 24 h, washed and 104 cells were co-cultured
with 5×104 CFSE-labelled CD4+ T cells. CFSE dilutions were analyzed
by ﬂow cytometry gated on CD4+ cells.2.10. Immunohistochemistry
Cells were cultured on gelatine-coated cover slips. For immuno-
histochemistry, cells were ﬁxed either in PBS containing 4%
paraformaldehyde [31]. PBS supplemented with 1% bovine serum
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ered as statistically signiﬁcant for pb0.05.
3. Results
3.1. GM-CSF differentiates heart-inﬁltrating CD133+ progenitor cells into
pathogenic DCs
In EAM, CD133+ cells inﬁltrating the myocardium represent a
non-committed progenitor cell type. Given the fact that GM-CSF
differentiates bone marrow progenitors into functional DC, we ﬁrst
asked whether GM-CSF differentiates heart-inﬁltrating CD133+ pro-
genitor cells into functional DCs. We immunized BALB/c mice with
two subcutaneous injections of αMyHC/CFA at days 0 and 7. At day
21, representing the peak of disease in EAM, we isolated CD133+
cells from diseased hearts, and plated and expanded them in vitro
for two weeks. Next, expanded cells were cultured in the presence
or absence of GM-CSF for additional 14 days. In cytokine-free, control
culture medium, expanded cells mainly expressed CD133 and CD11b,
but not the DCmarkers CD11c, MHC class II, CD80 or CD86 (Fig. 1A–H).
In contrast, GM-CSF exposure resulted in a loss of CD133 expression and
the development of a typical DC phenotype with high expression of
CD11b, CD11c, MHC class II, CD80 and CD86 (Fig. 1A–H).
Antigen uptake, procession, and presentation to T cells are key fea-
tures of DCs. We pre-incubated CD133+ progenitors and CD133+-
derived DCs with OVA peptide and added transgenic DO11.10-tg
CD4+ T cells recognizing OVA peptide. OVA-reactive CD4+ T cells be-
came activated and showed robust proliferation in co-cultures with
OVA-pulsed CD133+-derived DCs, but not CD133+ progenitors
(Fig. 2A). Moreover, OVA-reactive CD4+ T cells co-cultured with10 2 10 3 10 4 10 5 0 10 2 10 3 10 4 10 5
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naïve T cell marker — CD62L (Fig. 2B), and gained the expression of
activated T cell markers CD44 and CD69 (Fig. 2C–D).
Bone marrow-derived DCs generated in the presence of GM-CSF
were reported to induce EAM [4,24]. We therefore addressed, whether
CD133+-derived DCs can also effectively present self-antigen to in-
duce heart-speciﬁc, pathogenic Th cells. To this end, we loaded
bone marrow-derived DCs, GM-CSF-treated, and untreated CD133+
progenitors with αMyHC peptide, stimulated with LPS and anti-
CD40 and transferred them into recipient mice at days 0, 2 and 4.
Analysis of heart tissue sections at day 10 demonstrated that
GM-CSF-treated CD133+ cells were as efﬁcient in inducing myocar-
ditis as bone marrow-derived DCs. In contrast, untreated CD133+
progenitors failed to induce signiﬁcant inﬂammation of the heart
(Fig. 2E). Taken together, these data clearly demonstrate that GM-CSF
differentiates heart-inﬁltrating CD133+ cells into pathogenic, disease
inducing DCs.
We previously demonstrated immunosuppressive properties of
CD133+ progenitors. They inhibited T cell proliferation and attenuated
EAM through nitric oxide [5,31]. Next, we co-cultured control and
GM-CSF-treated CD133+ progenitors together with αMyHC-reactive
Th17 cell line in the presence of αMyHC-pulsed irradiated splenocytes
as antigen presenting cells. As expected, CD133+ progenitors nearly
completely inhibited proliferation of αMyHC-reactive CD4+ T cells. In
contrast, CD133+-derived DCs failed to suppress T cell proliferation
(Fig. 3A). Next, we immunized BALB/c mice with αMyHC/CFA and0 50K 10
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Fig. 5. GM-CSF treatment does not affect CD11c expression on CD133+ heart-inﬁltrating pr
either with PBS or 200 μg/kg GM-CSF at days 21 and 23. (A–B) Representative ﬂow cytometr
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fraction (D) in PBS-treated (black) or GM-CSF-treated (white) mice at day 24 of EAM. n=administered intravenously 2×106 of in vitro expanded cells at day 7
after the ﬁrst immunization. In line with previous ﬁndings [5,31],
animals treated with CD133+ progenitors were protected from myo-
carditis (Fig. 3B). In contrast, injection of CD133+-derived DCs did not
affect myocarditis severity at day 21 compared to αMyHC/CFA-
immunized and PBS-treated mice (Fig. 3B). Taken together, these data
suggest that GM-CSF-treated CD133+ progenitors lack immunosup-
pressive activity.3.2. GM-CSF boosted the accumulation of inﬂammatory DCs in EAM
GM-CSF effectively induces formation of functional DCs in vitro.
Next, we addressed whether GM-CSF can promote formation of DCs
during the early post-inﬂammatory phase, i.e. after day 21 of EAM. We
immunized BALB/c mice with αMyHC/CFA and starting from day 21
after the ﬁrst immunization injected every second day GM-CSF or PBS
into diseased animals. Systemic treatment with 200 μg/kg GM-CSF
resulted in accumulation of inﬂammatory CD11c+ DCs in the myocar-
dium at day 24 (Fig. 4A–B). This accumulation, however, was transient
only and not observed at later stages (not shown). Furthermore, the
population of CD11b+CD11c+ DCs, accumulating in the myocardium
in response to GM-CSF treatment, showed high expression of MHC II,
CD80 and CD86 (Fig. 4A,C). Importantly, GM-CSF treatment did not
affect the number of Gr-1-expressing cells at any stage (not shown).
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ﬂammatory DCs within the heart.
3.3. CD11b+ monocytes, rather than CD133+ progenitors represent the
dominant cellular source of heart-inﬁltrating inﬂammatory DCs in EAM
Next, we analysed potential cellular sources of inﬂammatory DCs
accumulating in hearts of GM-CSF treated mice. GM-CSF treatment af-
fected neither the percentage of CD133+ cells within inﬂammatory in-
ﬁltrates (Fig. 5A–C) nor CD11c expression on CD133+ cells at day 24
(Fig. 5A–B,D) or at later stages (not shown). Accumulation of inﬂamma-
tory DCs in EAM was observed as early as 3 days after GM-CSF treat-
ment. We therefore investigated whether heart-inﬁltrating CD133+
progenitors acquire a DC phenotype in response to GM-CSF within
3 days. Accordingly, we isolated heart-inﬁltrating CD133+ progenitors
from inﬂamed hearts at day 21 and treated them with GM-CSF. An in-
ﬂammatory DC phenotype was not evident earlier then 7 days of in
vitro culture in the presence of GM-CSF (Fig. 6A).
Inﬂammatory CD11b+CD11c− monocytes represent another po-
tential source of inﬂammatory, monocyte-derived DCs in EAM [30].0
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posed them to GM-CSF. As illustrated in Fig. 6B, 3 days was sufﬁcient
for monocytes to become MHC class II-expressing CD11c+ inﬂamma-
tory DCs. Thus, inﬂammatory CD11b+/CD11c– monocytes seem to
represent the dominant source of GM-CSF-induced inﬂammatory DC
hearts of mice with EAM.3.4. GM-CSF does not affect resolution of myocarditis, post-inﬂammatory
ﬁbrosis and T cell relapse
Accumulation of inﬂammatory DCs in response to GM-CSF may po-
tentially promote autoreactive T cell expansion, cardiac inﬂammation
and/or enhance ﬁbrosis. We immunized BALB/c mice with αMyHC/
CFA and treated them with GM-CSF or PBS every second day, starting
at day 21 of EAM. Unexpectedly, GM-CSF treatment did not affect the
number of CD45+ inﬂammatory and CD3+ T cells in cardiac tissue 3
(day 24) and 7 (day 28) days after cytokine treatment (Fig. 7A–B). We
also observed no differences in collagen deposition at days 24 and 28
(Fig. 7A–B).0
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At day 40, however, relapses of cardiac inﬂammation are common.
Relapses are characterized bymainly T cell inﬁltrates but overall inﬂam-
mation scores are lower compared to day 21. We therefore analyzed
whether GM-CSF treatment between days 21 and 29 affects T cell re-
lapse. Numbers of CD45+ and CD3+ T cells inﬁltrating themyocardium,
and the extent of cardiac ﬁbrosis did not differ between GM-CSF and
PBS treated mice at day 40 of EAM (Fig. 8A–C). Of note, treatment
with 100 and 500 μg/kg of GM-CSF also failed to affect ﬁbrosis develop-
ment (not shown). Furthermore, intravenous administration of GM-CFS
into αMyHC/CFA-immunized animals did not change total white blood
cell count, as well as the number of lymphocytes and monocytes in the
bloodstream. In contrast, we observed increased number of circulating
neutrophils at day 24 (Supplementary Fig. 1). Taken together, our
data suggest that GM-CSF treatment and cardiac accumulation of
inﬂammatory DCs after the peak of disease neither affect post-
inﬂammatory remodelling nor T cell relapses in EAM.
4. Discussion
A growing body of evidence suggests that hematopoietic cytokines,
naturally released in response to tissue injury, play a crucial role in
regulating inﬂammation and ﬁbrosis in various heart diseases [19].
GM-CSF represents one of the hematopoietic cytokines associated
with inﬂammation, however its role in inﬂammatory heart disorders
is poorly studied. Data from various animal models clearly point to a
pro-inﬂammatory role of this cytokine in inﬂammation [6,19]. Accord-
ingly, GM-CSF promotes development of CD4+ T cell-mediated auto-
immune myocarditis [25]. Previous reports [4,24,32] showed that
DCs generated with GM-CSF can induce heart-speciﬁc autoimmunity
indicating that GM-CSF-stimulated cells are potentially harmful in
myocarditis. However, transition from inﬂammation to ﬁbrosis, but
not inﬂammation per se, is critical for progressive heart failure and de-
velopment of the typical iDCM phenotype. So far, the contribution
of GM-CSF to resolution of myocardial inﬂammation and tissue
remodelling had not been addressed. Herein, we analyzed the role of
GM-CSF in the transition of acute myocarditis to post-inﬂammatoryiDCM. To address this question we used the EAM model. Because of
the EAM resistance observed in GM-CSF deﬁcient mice [25] we
chose a “gain of function” approach.
Our data showed that GM-CSF promoted formation of inﬂamma-
tory DCs in EAM. In the inﬂamed heart, we considered inﬂammatory
CD133+ progenitors and monocytes as two potential sources of
GM-CSF-induced DCs. We were able to demonstrate that both cell
types acquired an inﬂammatory DC phenotype upon GM-CSF stimula-
tion. We observed, however, different kinetics regarding expression
of DC-speciﬁc markers for these two cell populations. In response to
GM-CSF stimulation, monocytes acquired rapidly (i.e. within 3 days)
a phenotype of inﬂammatory DCs. This is not surprising, because a
subset of monocyte-derived DCs has been reported to be GM-CSF-
dependent under various inﬂammatory conditions [13,22,33]. In con-
trast, inﬂammatory CD133+ progenitors turned into inﬂammatory
DCs not earlier than 7 days after exposure to GM-CSF. These data sug-
gest that inﬂammatory monocytes, rather than CD133+ cells repre-
sent direct progenitors for DCs within the inﬂamed heart. We
cannot, however, entirely exclude recruitment of inﬂammatory DCs
from the bloodstream or other mechanisms promoting local accumu-
lation of inﬂammatory DCs in response to systemic GM-CSF delivery.
In the absence of exogenous GM-CSF, autoreactive Th17 cells rep-
resent an important source of GM-CSF [33–35], which could stimulate
development of inﬂammatory DCs in the target organ in EAM. Inter-
play between Th17 cells and inﬂammatory DCs can be proposed to
drive autoimmune inﬂammation. Inﬂammatory CD133+ progenitors
on the other hand, which effectively inhibit Th17 cell expansion,
seem to play a regulatory role in autoimmunity.
In our experiments, we observed a transient (at day 24, but not at
later) accumulation of inﬂammatory DCs in the myocardium of
GM-CSF-treated mice only. Importantly, there are very few inﬂamma-
tory cells in the heart at day 28 of EAM. We assume that the progres-
sive changes in the microenvironment, which parallels resolution of
inﬂammation successively suppress GM-CSF-induced CD133+ in-
ﬂammatory progenitor and bone marrow-derived CD11b+ monocyte
differentiation. In fact, published data link inﬂammatory conditions
with GM-CSF-dependent DC differentiation [11–13]. Alternatively,
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tial resolution of inﬂammation could also explain the only transient
accumulation of inﬂammatory DCs in EAM.
Cardiac inﬂammation resolves spontaneously in the EAMmodel. It
is not known which mediators maintain T cell expansion in the heart
and what mechanisms are decisive for resolution of active inﬂamma-
tion. One potential mechanismmaintaining autoreactive T cells in the
heart is the effective presentation of self-antigens by antigen
presenting cells. Here, we showed that inﬂammatory DCs expressing
MHC class II, and co-stimulatory molecules CD80 and CD86, represent
a potential cardiac self-peptide presenting cell population in the heart
[36]. GM-CSF treatment resulted in increased numbers of these DCs in
the post-inﬂammatory heart, but did not, however, affect the number
of heart-inﬁltrating T cells. Thus, it seems that inﬂammatory DCs do
not promote local T cell proliferation within the target organ in myo-
carditis. This observation contrasts the role of DCs in the lymphatic
system. In fact, GM-CSF promotes disease development in the early
phase of EAM by enhancing survival of antigen speciﬁc CD4+ T cells
[25]. Based on our ﬁndings we therefore suggest that maintenance
of active inﬂammation in EAM requires continuous migration of acti-
vated auto-reactive T cells from the lymphatic system to the heart.
Accordingly, activated T cells may have limited expansion capacitywithin the heart. From a biological point of view this makes sense.
Ongoing activation of auto-reactive cells by antigen presenting cells
at the target organ may result in a vicious cycle of self-destruction
and organ damage. The fact of spontaneous resolution of inﬂamma-
tion observed in the EAM model supports this hypothesis. Alterna-
tively cardiac self-antigens may be only insufﬁciently available for
inﬂammatory DCs within the heart, due to minimal necrosis and
cardiomyocyte cell death in the EAM model. Thus, we conclude a dis-
tinct role for inﬂammatory DCs in the lymphatic system and in in-
ﬂamed target.
Myocardial ﬁbrosis parallels heart failure progression in iDCM.
TGF-β signalling is crucial for ﬁbrosis development in EAM and
TGF-β-dependent conversion of inﬂammatory CD133+ progenitors
into myoﬁbroblasts represents one of the key mechanisms of post-
inﬂammatory cardiac ﬁbrosis [5]. Activated DCs and in particular
monocyte-derivedDCs arewell known toproduce a variety of cytokines
[37,38]. Interestingly, TGF-β production is limited to the speciﬁc subset
of tolerogenic CD8+ DCs [39], which represent a distinct population of
monocyte-derived DCs. We therefore assume that inﬂammatory DCs
are unable to directly trigger ﬁbrogenesis, however further studies are
needed to address the deﬁnitive role of the various chemokines and cy-
tokines produced by DCs in this process. GM-CSF also failed to induce
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ditis. It is therefore not surprising that the natural ﬁbroblast lineage dif-
ferentiation of CD133+ progenitors was unaffected. It seems that in
myocarditis pro-ﬁbrotic mediators, such as TGF-β successfully compete
with ex vivo administrated GM-CSF in directing the fate of inﬂammatory
CD133+ progenitors. To our knowledge, there are no data showing the
role of DCs in the post-inﬂammatory myocardium. Based on the obser-
vation that GM-CSF failed to regulate inﬂammation, we assume that the
local balance of pro-ﬁbrotic factors was comparable in GM-CSF-treated
and control mice. Apparently, GM-CSF did not trigger any othermecha-
nisms promoting or inhibiting pathological remodelling in the
post-inﬂammatory heart. Nevertheless, we cannot rule out that intrave-
nously administrated GM-CSF might affect the extracellular matrix and
the balance of metalloproteinases, their inhibitors, and speciﬁc cyto-
kines or growth factors.
Relapses of inﬂammatory cells are quite common in autoimmune
diseases [40,41], but little is known about the related mechanisms.
In BALB/c mice, we observed spontaneous inﬂammatory relapses
40 days after the ﬁrst immunization. GM-CSF treatment, however,
did not affect later relapses in EAM.
The role of GM-CSF has been addressed in ischemic cardiovascular
disorders too. In an animal model of myocardial infarction, GM-CSF
inducer exacerbates early left ventricular post-infarction remodelling
[42,43]. Of note, induction of GM-CSF promoted formation of DCs
within the infracted area in this model [43]. Other studies also point-
ed to a direct pro-angiogenic role of GM-CSF [44,45]. Importantly,
GM-CSF levels are elevated in various cardiovascular disorders in-
cluding myocarditis [17], ischemic dilated cardiomyopathy or arterial
hypertension [20,21,46]. Furthermore, GM-CSF is routinely used in
the clinic to mobilize stem cells from bone marrow into the blood-
stream [47]. From these points of view, our understanding of the
role of GM-CSF is of up-most importance. On the basis of our ﬁndings
and published data, it seems that GM-CSF therapy is not an attractive
option to treat inﬂammatory heart diseases. This is in marked con-
trast to other hematopoietic cytokines, such as G-CSF and M-CSF [6].
In summary, we here demonstrated for the ﬁrst time that GM-CSF
promotes formation of inﬂammatory DCs from heart-inﬁltrating
monocytes and progenitors in EAM. Despite transient accumulation
of inﬂammatory DCs in the inﬂamed heart, however, GM-CSF treat-
ment did not affect spontaneous resolution of inﬂammation, tissue
ﬁbrosis or pathological remodelling.
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